Big movers on D-Street: What should investors do with TCS, Natco Pharma and GRSE?

October 11, 2024

Domestic markets closed lower despite the RBI hinting at a rate cut. TCS is showing strong technical resilience and poised for an upward reversal, making it a ‘buy on dips’ candidate. Natco Pharma is in a healthy consolidation phase with potential targets of Rs 1,650–1,720.

More To Explore

Market rotation signals steady growth ahead; financials and PSUs lead the charge: Rohit Srivastava

According to Rohit Srivastava, the Indian market is experiencing sector rotation, ensuring upward movement after consolidation. Financials, especially NBFCs, are leading the rally due to

May 28, 2025

Defence sector has strong tailwinds, but valuations are sky-high: Dinshaw Irani

Dinshaw Irani of Helios Mutual Fund discusses investment strategies. He favors new-age companies and highlights quick commerce potential. Irani expresses optimism about Eternal and fintech

May 28, 2025

Advertiser Disclosure

Great-investor.com helps users across the globe to find out The latest news, Guides, and Info about finance and investments. Furthermore, our content and research teams do not participate in any advertising planning nor are they permitted access to advertising campaign data.

Disclaimer

It is our organization’s primary mission to provide reviews, commentary, and analysis that are unbiased and objective. While great-investor.com has some data verified by industry participants, it can vary from time to time. Operating as an online business, this site may be compensated through third party advertisers. Our receipt of such compensation shall not be construed as an endorsement or recommendation by great-investor.com, nor shall it bias our reviews, analysis, and opinions. Please see our General Disclaimers for more information

Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003